RCS - Physiomics PLC - Senior Management Announcement

PhysiomicsAnnouncement

03/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231003:nRSC4427Oa&default-theme=true

RNS Number : 4427O  Physiomics PLC  03 October 2023

3 October 2023

 

Physiomics plc

("Physiomics" or "the Company")

 

Senior Management Announcement

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions, is pleased to announce the hiring this week of a new
senior member of its team, Dr Venkata Putcha, as Head of Biostatistics.

 

Dr Putcha brings with him over 22 years of experience working within drug
development, with over 17 years working for many of the top-tier
pharmaceutical and CRO companies. Since obtaining his PhD in Applied
Statistics, he has held a variety of senior biostatistics and programming
roles across academia and industry, both working in-house and as an
independent consultant. During these roles, he gained significant experience
across Pre-clinical, PK/PD, Biosimilars, Phase-I, IIa, IIb, III and IV,
Medical Affairs, Post-Marketing, Diagnostics, Medical Devices, Heath
Technology Assessments, Health Economics and Health Related Quality of Life
analysis.

 

The Head of Biostatistics role will help to formulate and deliver on the
Company's new Biostatistics service offering. The initial focus will be to
build upon the Company's existing Biostatistics strategy, working with
Business Development and Senior Management to define key service offerings and
identify new clients. Dr Putcha will be responsible for the delivery of new
Biostatistics consulting contracts within the business and, as we grow this
service line, will take a lead refining and executing on the Company's
Biostatistics strategy.

 

Dr Jim Millen, Executive Chair and CEO commented:

 

"Following our announcement earlier this year that Physiomics would be
expanding into adjacent areas of lifesciences R&D consulting, starting
with biostatistics, we are delighted to welcome Venkata to our team.  His
extensive experience in the field of biostatistics will act as a strong base
from which to grow this new segment of our business.  We'll be providing a
further update on our expansion into this field later this calendar year."

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with
cancer biology expertise, to help biotech and pharma companies streamline
their drug development journeys.

 

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design of pre-clinical and clinical studies.

 

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 commercial
projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADLLFBXBLEFBX